In this episode, Joe interviews Seth Rosenberg: Washington DC-based mycologist and anti-drug war advocate who worked on DC's decriminalization Initiative 81, and who was presumably arrested for purchasing legal plants online.
www.psychedelicstoday.com
In this episode, David interviews Jim Gilligan: Interim CEO and Chief Scientific Officer of Tryp Therapeutics, a biotech company researching psychedelics for the treatment of eating disorders and nociplastic pain.
www.psychedelicstoday.com
In this episode, Joe interviews transformational coach and guide, Brenna Gebauer; in-person from her parents' RV at this year's Lightning in a Bottle festival, with facilitator and past guest, Mark Haberstroh stopping in too.
www.psychedelicstoday.com
In this episode, David interviews globally-recognized cannabis activist, author, entrepreneur, speaker, podcaster, and “Father of the Legal Cannabis Industry,” Steve DeAngelo; discussing industry, decriminalization, and more!
www.psychedelicstoday.com
In this episode, Joe interviews Christopher Koddermann: Co-Founder of the International Therapeutic Psilocybin Rescheduling Initiative (ITPRI). He discusses patents, IP, and what needs to be done to reschedule psilocybin.
www.psychedelicstoday.com
In this episode, David interviews Kevin Balktick: Founder & Director of Horizons; one of the world's longest-running psychedelic media and education communities, which is expanding to Portland, Oregon this year with Horizons NW.
www.psychedelicstoday.com
In this episode, "Vital Psychedelic Conversations" returns with Kyle interviewing Steve Thayer: psychologist, Clinical Director of Education & Training at Novamind, and co-host of the Psychedelic Therapy Frontiers podcast.
www.psychedelicstoday.com
In this episode, David interviews Susan Beaulieu: Extension Educator at the University of Minnesota Extension, who works with her community (the Anishinaabe people) around intergenerational trauma and community resilience.
www.psychedelicstoday.com
In this episode, Joe interviews Soren Shade: producer of the third season of “Hamilton’s Pharmacopeia" and Co-Founder of Top Tree Herbs, a kratom tea company dedicated to educating people about kratom and normalizing its use.
www.psychedelicstoday.com
In this episode, Victoria Dekker debuts, interviewing the CEO of TheraPsil, Spencer Hawkswell, about the charter challenge that effectively sues the Canadian government for ending psilocybin exemptions for end-of-life patients.
www.psychedelicstoday.com
In this episode, David interviews Monnica Williams, Ph.D. She discusses the mental health impact communities of color face as a result of racism; and what therapists, clinicians, and researchers can do to improve this paradigm.
In this episode, David interviews Joost Breeksema: Executive Director of the OPEN Foundation, which manages the Interdisciplinary Conference on Psychedelic Research (ICPR) which returns to Amsterdam this September 21-24.
www.psychedelicstoday.com
In this episode, Joe interviews Kim Dudine: Chief of Staff at OpenNest Labs and Director of Membership and Strategy at Trailblazers Presents. She discusses the benefits, psychedelic nature, and unifying aspects of cannabis.
www.psychedelicstoday.com
In this episode, Joe interviews Melissa Lavasani: Founder and Executive Director of the Psychedelic Medicine Coalition, proposer of DC's Initiative 81, and interviewee in Michael Pollan's "How to Change Your Mind" docuseries.
In this episode, David interviews Lauren Katalinich & Anya Oleksiuk of the Psychedelic Society, a website/community that runs events and works to build the community so many people need after having a psychedelic experience.
www.psychedelicstoday.com
In this episode, David interviews Sisi Li, Ph.D.: Data Architect for Porta Sophia; a non-profit online library collecting relevant prior art in the world of psychedelics for innovators and patent reviewers around the world.
www.psychedelicstoday.com
In this episode, Joe interviews Christopher Dawson & Andrew Galloway: Co-Founders and CEO/COO, respectively, of Dimensions; a company creating retreats blending traditional plant ceremony with modern science and 5-star luxury.
www.psychedelicstoday.com
In this episode, David interviews David Nutt: Psychiatrist, Founder/Chief Scientific Officer at Drug Science, Chief Research Officer at Awakn Life Sciences, and Professor of Neuropsychopharmacology at Imperial College London.
www.psychedelicstoday.com
In this episode, Joe interviews T. Cody Swift, MFT, and Miriam Volat, MS; Co-Directors of The Riverstyx Foundation. They discuss plant medicine bioculture; peyote conservation, and working for the survival of Indigenous culture.
www.psychedelicstoday.com
In this episode of the podcast, Joe interviews James Lanthier, the CEO of Mindset Pharma; a biotechnology company discovering and developing new (and hopefully safer, more predictable, and more palatable) psychedelic compounds.
www.psychedelicstoday.com
In this episode, Joe interviews Julie Zukof: Head of Strategic Partnerships for Nue Life and the creator of Psychedelic Women, and Michelle Weiner: a double board-certified Doctor specializing in integrative pain management.
www.psychedelicstoday.com
In this episode, Joe interviews Dick Simon: Co-Founder and CEO of Sensorium Therapeutics, an organization created to research plants we already know are effective and synthesize new ones. How can we best optimize what we know?
www.psychedelicstoday.com
In this bonus episode, Kyle interviews Dr. Scott Shannon: Co-Founder and CEO of the Board of Psychedelic Medicine and Therapies; a non-profit created to certify healthcare professionals in psychedelic-assisted psychotherapy.
www.psychedelicstoday.com
In this episode, Joe interviews Licensed Marriage & Family Therapist and Founder of Access To Doorways, Courtney Watson. Watson talks about ancestral practices, Diasporic religions, & trauma healing for QTBIPOC communities.
www.psychedelicstoday.com
In this episode, David interviews Founder and Executive Director of MAPS, Rick Doblin, Ph.D. He discusses the abuse allegations unearthed in the recent “Cover Story” podcast series, real-world evidence, and MAPS' future goals.
www.psychedelicstoday.com